CRMD · CorMedix Inc.
$7.78
-0.64 (-7.60%)
At close · Jul 20
Market Cap
$610.36M
Shares
78.45M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$311.71M
+617%
FY2025
Net Income
$163.06M
+1009.4%
FY2025
Gross Margin
88.46%
-4.2pp
FY2025
Operating Margin
48.17%
+99.6pp
FY2025
Diluted EPS
$2.04
+780%
FY2025
Operating Cash Flow
$175.05M
+445.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $325M – $345M | $400.05M | $311.71MG | $43.47M | — | $65.41K | $190.94K | $239.23K | $283.27K | $429.8K | $329.33K | $224.11K | $210.13K | $189.27K | $2001 | $0 | — | — | — | — | — | |
| — | — | — | $1.4M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | $4000 | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $32.55M | $22.09M | $3.03M | — | $3734 | $148.94K | $204.85K | $373.23K | $396.79K | $114.96K | $366.67K | -$318.72K | -$445.8K | -$201.61K | $0 | — | — | — | — | — | |
| — | $343.39M | $275.75M | $40.28M | — | $61.67K | $42K | $34.39K | -$89.97K | $33.01K | $214.36K | -$142.57K | -$108.59K | -$256.53K | -$199.6K | $0 | — | — | — | — | — | |
| — | — | 88.46% | 92.66% | — | 94.29% | 22% | 14.37% | -31.76% | 7.68% | 65.09% | -63.62% | -51.68% | -135.53% | -9975.21% | — | — | — | — | — | — | |
| — | $23.35M | $19.33M | $3.94M | $13.16M | $10.68M | $13.13M | $13.38M | $11.05M | $18.82M | $24.49M | $15.74M | $6.28M | $1.32M | $1.23M | $1.14M | $4.06M | $5.49M | — | — | — | |
| — | $46.11M | $38.05M | $28.74M | $18.12M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $80.25M | $68.22M | $29.96M | $17.69M | — | — | — | — | $8.07M | $8.65M | $8.88M | $10.26M | $7.33M | $3.49M | $1.86M | $3.15M | $3.01M | — | — | — | |
| — | $43.24M | — | — | $35.8M | $20.01M | $16.35M | $13.88M | $9.87M | $8.07M | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | $13.87M | $156K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $149.71M | $125.61M | $62.64M | $48.96M | $30.69M | $29.48M | $27.26M | $20.92M | $26.9M | $33.14M | $24.62M | $16.55M | $8.65M | $4.72M | $3M | $7.21M | $8.51M | — | — | — | |
| — | — | — | — | — | — | $3.01M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $193.67M | $150.14M | -$22.36M | -$48.96M | -$30.62M | -$29.44M | -$27.22M | -$21.01M | -$26.86M | -$32.92M | -$24.76M | -$16.65M | -$8.9M | -$4.92M | -$3M | -$7.21M | -$8.51M | — | — | — | |
| — | — | 48.17% | -51.43% | — | -46819.91% | -15417.51% | -11378.44% | -7416.31% | -6250.44% | -9997.39% | -11048.8% | -7925.56% | -4703.3% | -245646.93% | — | — | — | — | — | — | |
| — | — | $2.78M | $36K | $34.3K | $26.52K | $15.94K | $33.23K | $787.49K | $1873 | $5619 | $1311 | $3964 | $2087 | $1.44M | $382.94K | $0 | $3.09M | — | — | — | |
| — | — | $3.85M | $2.58M | $2.68M | — | — | $116.07K | $322.67K | $36.62K | $110.71K | $126.77K | $60.39K | $2714 | $668 | $1965 | $12.04K | $23.44K | — | — | — | |
| — | -$8.66M | -$125K | $3.03M | $2.62M | $336.65K | -$22.83K | $23.67K | -$485.98K | $34.57K | -$85.8K | — | — | — | — | — | — | — | — | — | — | |
| — | -$4357 | — | — | — | — | — | — | $268 | $0 | $13.1K | $11.03K | -$24.24K | $0 | — | — | — | — | — | — | — | |
| — | $185.02M | $150.02M | -$19.33M | -$46.34M | -$30.29M | -$29.46M | -$27.2M | -$21.49M | -$26.83M | -$33.01M | -$24.64M | -$18.19M | -$20.45M | -$9.13M | -$3.38M | -$7.17M | -$11.19M | — | — | — | |
| — | $4.01M | -$13.04M | -$1.4M | — | -$585.62K | -$1.25M | -$5.17M | -$5.06M | — | — | — | — | — | -$774.78K | $0 | -$493.86K | -$280.92K | — | — | — | |
| — | $181.01M | $163.06M | -$17.93M | -$46.34M | -$29.7M | -$28.21M | -$22.03M | -$16.43M | -$26.83M | -$33.01M | -$24.64M | -$18.19M | -$20.45M | -$9.13M | -$3.38M | -$6.67M | -$10.91M | -$8.12M | -$9M | -$7.24M | |
| — | — | 52.31% | -41.24% | — | -45409.9% | -14774.7% | -9207.7% | -5801.29% | -6242.4% | -10023.45% | -10996.46% | -8655.37% | -10806.25% | -456426.69% | — | — | — | — | — | — | |
| — | — | — | — | — | — | $28.2M | $22M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | -$22.03M | -$43.54M | -$26.83M | — | -$24.64M | -$18.22M | -$20.54M | -$9.52M | -$3.38M | — | — | — | — | — | |
| — | -$83K | -$88K | -$3000 | -$46.33M | -$29.71M | -$28.23M | -$22.02M | -$16.43M | -$26.83M | -$32.99M | -$24.62M | -$18.22M | -$20.35M | -$9.14M | — | — | — | — | — | — | |
| USD/shares | — | — | $2.25 | -$0.30 | -$0.91 | -$0.74 | -$0.75 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | — | $2.04 | -$0.30 | -$0.91 | -$0.74 | -$0.75 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | — | 72.03K | 58.87K | 50.9M | 40.27M | 37.67M | 28.56M | 24.15M | 17.82M | 55.14M | 37.97M | 31.34M | 21.44M | 13.82M | 11.41M | 11.41M | — | — | — | — |
| shares | — | — | 80.31K | 58.87K | 50.9M | 40.27M | 37.67M | 28.56M | 24.15M | 17.82M | 55.14M | 37.97M | 31.34M | 21.44M | 13.82M | 11.41M | 11.41M | — | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.46×
EV/EBIT
—
Biotechnology median 26.45×
P/E (TTM)
3.59×
Biotechnology median 7.03×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2021 | FY2020 | FY2019 |
|---|---|---|---|
| Europe | $190,936 | $237,025 | $274,443 |
By Product & Service (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Product | $304,344,000 | — |
| DefenCath | $258,813,000 | $43,472,000 |
| Melinta Portfolio | $45,531,000 | — |
| Contract Revenue | $7,365,000 | — |
Key facts
CIK
1410098
CUSIP
21900C308
13F (30d)
14 filings
14 filers
Visit website
Investor relations